

DR. ARIJIT NAG

Address:

TATA Medical Center,
14, Main Arterial Road (E-W),
DH Block, New town,
Kolkata: 700160.

Phone :

Work: (+91)-33-66057832
Mobile: (+91)-9051121161.

Email: arijit.nag@tmckolkata.com, drarijitnag@gmail.com

Current Position: Physician Investigator.

Consultant (in the rank of Associate Professor), (July 2022 to present)
Department of Clinical Hematology and BMT,
TATA Medical Center, Kolkata

Clinical Lead, Adult Leukemia Group,
Clinical Lead, Compassionate drug access program,
TATA Medical Center, Kolkata. Jan 2022 to present.

Education and Certifications:

1. **Undergraduate Medical Education: MBBS:** Aug 2004 to April 2010 : NRS Medical College, WBUHS.
2. **Post-Graduate training (Residency): MD (Internal Medicine):** June 2011 to May 2014: Institute of Post-Graduate Medical Education and Research, Kolkata, West-Bengal, India
3. **Post-Doctoral Training (Clinical Fellowship): DM (Clinical Hematology):** Aug 2014 to July 2017: Institute of Hematology and Transfusion Medicine, Medical College and Hospitals, Kolkata.
4. **Additional Speciality Qualifications: MRCP(UK):** 2017: Royal College of Physicians, UK
5. **Post-Doctoral Fellowship in Hematology and Bone Marrow Transplantation,** Tata Medical Center, Kolkata: Sep 2018 to March 2019
6. **Clinical Fellowship in Allogeneic Stem cell transplant, University of Toronto:** April 2019 to June 2020.

Prior professional Experience

Position/Title	Name and Location of Institution	Timeline
----------------	----------------------------------	----------

Consultant (Rank of Associate Professor)	Department of Clinical Hematology and Cellular therapy, TATA Medical Center, Kolkata, West Bengal, India	July 2022 to present
Consultant (Rank of Assistant Professor)	Department of Clinical Hematology and Cellular therapy, TATA Medical Center, Kolkata, West Bengal, India	July 2020 to July 2022
Previous		
Clinical Fellow	Allogeneic BMT Program, Department of Hematology and Medical Oncology, Princess Margaret Cancer Center, University of Toronto.	April 2019 – June 2020
Senior Fellow	Department of Clinical Hematology and Cellular therapy, TATA Medical Center, Kolkata, West Bengal, India	Sep 2018 – March 2019
Associate Consultant	Department of Hematology, Medical College, Kolkata	Sep 2017-Sep 2018
Senior Resident	Department of Hematology, Medical College, Kolkata	Aug 2014 – July 2017
Junior Resident	Institute of Post-Graduation Medical Education and Research, Kolkata	June 2011 – May 2014

Work experience:

- Rotational Internship Training: Nil Ratan Sircar Medical College and Hospital, March 2009 to March 2010 with postings in the department of Internal Medicine, General Surgery, Community medicine, Gynaecology, Paediatrics, Otorhinolaryngology and Ophthalmology and allied specialties.
- House-staffship in Emergency Medicine, Nil Ratan Sircar Medical College and Hospital, Kolkata, West Bengal, India: January 2011 to April 2011: Attended to critically ill patients in the emergency. Main areas of work consisted of triaging patients in emergency room (ER), immediate resuscitation, management of clinical emergencies as per protocol under supervision of Senior medical officer from ER.
- Junior-Resident (Academic): Department of Medicine, IPGME&R and SSKM Hospitals, Kolkata, West Bengal, India: June 2011-May 2014
(Towards specialty training in Internal Medicine for the degree MD (Internal Medicine))

- Senior-Resident (Academic), Institute of Hematology and Transfusion Medicine, Medical College and Hospital, Kolkata, West Bengal, India: August 2014 – July 2017

(Towards Clinical Fellowship In Hematology for the degree DM (Clinical Hematology))

1. Discuss treatment options and diagnostics with patients and families
2. Closely examine patients' medical history, treatment protocol, physical condition and test results and decide and execute the treatment protocol.
3. Maintain accurate medical records and document patient case-history in detail.
4. Continuously work to improve performance at an individual level and as part of the team of physicians.
5. Administer chemotherapy and immunotherapy medications to In-patients and In day-care facility
6. Attend to patients in general out-patient department and in special-clinics (Thalassemia, Hemostasis, Acute Leukemia, Lymphoma, Myeloma and Transplant, Chronic Leukemia).
7. Managing Stem Cell Transplant patients including pre-transplant work-up, transplant-proper and post-transplant care, peripheral blood stem cell collection procedure, bone marrow harvest procedures. Was part of treating team in 10 autologous and 3 allogeneic stem cell transplants.
8. Trained in Hematopathology including Peripheral blood film, Bone Marrow Aspirate and Biopsy reporting and reporting of Flow Cytometry data.
9. Undertook research projects pertaining to Thalassemia, Aplastic Anemia and Hemophilia.
10. Participated in Clinical meetings and Journal Club/Scan.
11. Engaged in training junior colleagues in Internal Medicine and Hematology.

- Junior Consultant, Hematology: Institute of Hematology and Transfusion Medicine, Medical College and Hospital, Kolkata, West Bengal, India: Sep 2017 – Sep 2018.

- Outpatient clinics in general hematology, hemoglobinopathies, hemostasis, leukemia and bone marrow transplant follow up.
- Part of clinical team performing stem cell transplants (4 autologous stem cell transplants and 1 allogeneic stem cell transplant).

- Senior Fellow in the Department of Hematology and Bone Marrow Transplantation: Tata Medical Center, Kolkata: Sep 2018 to March 2019

- Trained in advanced management of hematologic malignancies including acute leukaemia, lymphoma, multiple myeloma and plasma cell dyscrasia, benign haematology (including hemoglobinopathies).
- Trained in stem cell transplantation with clinical posting in the BMT unit for 4 months. Trained in clinical care of patients (adult and paediatric) undergoing stem cell transplantation (autologous and allogeneic) including:
 - Pre-transplantation workup of recipients, protocol development and making prescriptions, and post transplant follow-up care.
 - Workup of stem cell donors, including donor counselling, stem cell collection (apheresis), bone marrow harvest and post-donation follow up.
 - Managing acute and long term complications of SCT.
 - Training education activities of the department of clinical hematology and BMT, during the tenure of fellowship.

- Participated in 8 PBSC apheresis and 3 bone marrow harvests during the fellowship tenure.
- Clinical Fellow, Massner Allogeneic Blood and Marrow Transplant Program, Princess Margaret Hospital, University of Toronto. May 2019 to July 2020.
Advanced clinical fellowship in stem cell transplantation in allogeneic stem cell transplantation in the largest allogeneic stem cell transplant program in Canada; Trained in allogeneic stem cell transplantation with:
 - Clinical posting in the adult allo-SCT program. Clinical postings in outpatient clinics and inpatient and acute care rotations.
 - Pre-transplantation workup of recipients, protocol development and post-transplant follow-up care.
 - Workup of stem cell donors, including donor counselling, stem cell collection (apheresis), bone marrow harvest and post-donation follow up.
 - Managing acute and long term complications of allo-SCT.
 - Participated in 8 bone marrow harvests during the fellowship tenure.
 - Training education activities of the allo-transplant program during the tenure of fellowship.
 - Participated in clinical research including clinical audits and a prospective study looking at 'formulating and validation of a frailty and functionality score predicting outcomes in patients undergoing allo-SCT'.

Honors and Awards:

1. **International CML Federation Preceptorship 2017** : under Prof. Jorge Cortes in Department of Leukemia, the MD Anderson Cancer Center, Texas.
2. **Travel grant for ASH Highlights in Asia-Pacific, 2018 at Bali, Indonesia** : Awarded to 5 hematologists by the Indian Society of Hematology and Blood Transfusion (ISHBT).
3. **University medal for the best outgoing student in Hematology, 2017** awarded by the West Bengal University of Health Sciences.
4. **Runner's Up in Best Poster presentation** in Annual Congress of Indian Society of Hematology and Blood Transfusion (ISHBT) : Haematocon 2017, Section: Benign Hematology, Clinical

Scientific community roles:

- **Journals:**
 - o Reviewer for Indian Journal of Hematology and Blood Transfusion
 - o Reviewer for Pediatric Hematology Oncology Journal
 - o Reviewer for BMC Cancer
- **Members of Professional Bodies:**
 - Indian Society of Haematology and Blood Transfusion (Life Member)
 - Indian Society of Bone Marrow Transplant (ISBMT): Active member.
 - American Society of Haematology (ASH) (International member)
 - American Society of Clinical Oncology (ASCO), International Member.

- Cell Therapy and Transplant Canada (Formerly CBMTG); Member
- American Society of Transplant and Cellular Therapy (ASTCT) (formerly ASBMT)
- International CML Federation (ICMLF)

- Institutional Committee positions:
 - o Reviewer of Intramural grants.

Educational Roles and Teaching:

- Faculty for Fellowship training in the Clinical Hematology and BMT program under the National Board of Examinations (NBE), DrNB Clinical Hematology.

Mentorship:

1. Dr. Suchita Shinde, MD
Description: Formal fellowship mentor, monthly contact, May 2022 – Present
Current status: Clinical Fellow, Adult Hematology Program
Outcome:
 - Dissertation on comprehensive genomic profiling of AYA and adult ALL patients being treated on a pediatric inspired treatment regimen.
 - Abstract accepted for poster presentation at Annual Congress of ISHBT, 2022.

Grants

- Unrestricted scientific grant from Bayer for establishing a comprehensive cancer thrombosis register at TATA Medical Center, Kolkata.

Peer reviewed manuscripts : Hematology focus

1. CORTES, J. E., KIM, D.-W., SAIKIA, T., KHATTRY, N., RATHNAM, K., ALVARADO, Y., HANNAH, G., TANTRAVAH, S. K., APPERLEY, J. F. & CHARBONNIER, A. 2025. Vodobatinib for patients with Philadelphia chromosome-positive chronic myeloid leukaemia resistant or intolerant to multiple lines of previous therapy: an open-label, multicentre, phase 1/2 trial. *The Lancet Haematology*.
2. Nag A, Radhakrishnan VS, Kumar J, Bhav S, Mishra DK, Nair R, Chandy M. Thalidomide in Patients with Transfusion-Dependent E-Beta Thalassemia Refractory to Hydroxyurea: A Single-Center Experience. *Indian J Hematol Blood Transfus*. 2020 Apr;36(2):399-402. doi: 10.1007/s12288-020-01263-2. Epub 2020 Mar 2. PubMed PMID: 32425398; PubMed Central PMCID: PMC7229140.
3. Biswas S, Nag A, Ghosh K, Ray R, Roy K, Bandyopadhyay A, Bhattacharyya M. Genetic determinants related to pharmacological induction of foetal haemoglobin in transfusion-dependent HbE-β thalassaemia. *Ann Hematol*. 2019 Feb;98(2):289-299. doi: 10.1007/s00277-018-3536-x. Epub 2018 Nov 9. PubMed PMID: 30413899.
4. Nag A, Ghosh S, Sinha D, Mondal S, Roy SS, Ghosh A, Bhattacharyya M. Ultrasonography of Knee Joint in Hemophilia A: What the Eyes Cannot See. *Indian J Hematol Blood Transfus*. 2019 Jan;35(1):149-154. doi: 10.1007/s12288-018-0974-5. Epub 2018 Jun 18. PubMed PMID: 30828163; PubMed Central PMCID: PMC6369076.
5. Nag A, Bhattacharyya M. Rivaroxaban Induced Thrombocytosis: A Perplexing Clinical Challenge. *Indian J Hematol Blood Transfus*. 2018 Oct;34(4):772-773. doi: 10.1007/s12288-018-0935-z. Epub 2018 Mar 5. PubMed PMID: 30369764; PubMed Central PMCID: PMC6186222.
6. Sinha S, Chatterjee SS, Biswas M, Nag A, Banerjee D, De R, Sengupta A. SWI/SNF subunit expression heterogeneity in human aplastic anemia stem/progenitors. *Exp Hematol*. 2018 Jun;62:39-44.e2. doi: 10.1016/j.exphem.2018.03.005. Epub 2018 Mar 27. PubMed PMID: 29596882.
7. Vs R, D P, H M, P M, R A, S S, D D, I A, Z L, N A, A N, J K, R J, S J, B, M P, Dk M, M C, R N. Primary Central Nervous System Lymphoma: Long-Term Treatment Outcomes and Cost-Analysis from a Retrospective Study of High-Dose Methotrexate Based Chemotherapy and Reduced Dose Radiation Therapy Approach. *Indian J Hematol Blood Transfus*. 2022 Apr;38(2):223-234. doi: 10.1007/s12288-021-01444-7. Epub 2021 May 18. PubMed PMID: 35496970; PubMed Central PMCID: PMC9001787.

8. Radhakrishnan VS, Bajaj R, Raina V, Kumar J, Bhawe SJ, Sukumaran Nair RK, Nag A, Arun I, Zameer L, Dey D, Arora N, Parthar M, Das J, Achari RB, Mishra DK, Chandy M, Nair R. Relapsed Refractory Hodgkin Lymphoma and Brentuximab Vedotin-Bendamustine Combination Therapy as a Bridge to Transplantation: Real-World Evidence From a Middle-Income Setting and Literature Review. *Front Oncol.* 2021;11:796270. doi: 10.3389/fonc.2021.796270. eCollection 2021. PubMed PMID: 35127505; PubMed Central PMCID: PMC8814627.
9. Pindia R, Radhakrishnan V, Kumar J, Nag A, Bhawe S, Zameer L, Vinarkar S, Das J, Mishra D, Chandy M. Refractory Primary Mediastinal B-Cell Lymphoma: A Case Report of Conventional Chemotherapies, Immune Checkpoint Inhibitors, Polatuzumab Vedotin, Transplantation, and Post-Transplant Large Granular Lymphocytosis. *Indian Journal of Medical and Paediatric Oncology.* 2022.
10. Javed R, Roychowdhury M, Bhawe S, Nag A, Kumar J, Radhakrishnan V, Bhattacharya S, Mishra D, Ghara N, RS R. Impact of COVID-19 on peripheral stem cell collection and preservation at a hematopoietic cell transplant center in India: Experience 2020. *Blood Cell Ther.* 2021; 4:84-87.
11. Shaw J, Chakraborty A, Nag A, Chattopadhyay A, Dasgupta AK, Bhattacharyya M. Intracellular Iron overload leading to DNA damage of lymphocytes and immune dysfunction in thalassemia major patients. *Eur J Haematol.* 2017 Nov;99(5):399-408. doi: 10.1111/ejh.12936. Epub 2017 Sep 13. PubMed PMID: 28815805.

Peer reviewed manuscripts : Non Hematology focus

1. Nag A, Datta J, Das A, Agarwal AK, Sinha D, Mondal S, Ete T, Chakraborty A, Ghosh S. Acute kidney injury and demonecrosis after *Loxosceles reclusa* envenomation. *Indian J Nephrol.* 2014 Jul;24(4):246-8. doi: 10.4103/0971-4065.133017. PubMed PMID: 25097339; PubMed Central PMCID: PMC4119339.
2. Arjitt N, Sinha D, Mondal S, Chakraborty A, Ghosh A. Carpal tunnel syndrome as a presenting feature of polymyositis: a case report from India. *Archives of Rheumatology.* 2014; 29(3):224-227.
3. Sinha D, Mondal S, Nag A, Ghosh A. Development of a colour Doppler ultrasound scoring system in patients of Takayasu's arteritis and its correlation with clinical activity score (ITAS 2010). *Rheumatology (Oxford).* 2013 Dec;52(12):2196-202. doi: 10.1093/rheumatology/ker289. Epub 2013 Sep 6. PubMed PMID: 24014648.
4. Sinha D, Nag A, Mondal S, Ghosh A. A80761 Comparison Between Colour Doppler Ultrasound and MRI in Documenting Response to Treatment with Nsaids and in Assessing Disease Activity in Non-Radiographic Spondyloarthritis. *BMJ Publishing Group Ltd;* 2015. 0003-4967.
5. Ghosh A, Mondal S, Sinha D, Nag A, Chakraborty S. Comment on: Ultrasonography as a useful modality for documenting sacroiliitis in radiographically negative inflammatory back pain: a comparative evaluation with MRI: reply. *Rheumatology (Oxford).* 2015 Aug;54(8):1535. doi: 10.1093/rheumatology/kev127. Epub 2015 Jun 3. PubMed PMID: 26044043.
6. Sinha D, Nag A, Mondal S, Ghosh a. Comparison between colour doppler ultrasound and mri in documenting response to treatment with nsaid and in assessing disease activity in non-radiographic spondyloarthritis. *Annals of the rheumatic diseases.* 2015; 74:1153-1153.
7. Sinha D, Mondal S, Nag A, Lahiri D, Ghosh A. Clinical and doppler monitoring of patients with Takayasu arteritis with ITAS 2010 and CDUS-K score respectively following medical intervention: a 12 months follow-up study. *International Journal of Research in Medical Sciences.* 2018; 6(11):3602.
8. Mondal S, Sinha D, Nag A, Chakraborty A, Ete T, Ghosh A. Sterno clavicular joint osteoarthritis In a patient with rheumatoid arthritis a case report with Classical sonographic features. *Journal of Diagnostic Medical Sonography.* 2015; 31(3):186-189.
9. Mondal S, Sinha D, Nag A, Chakraborty A, Ete T, Ghosh A. Sterno clavicular joint osteoarthritis In a patient with rheumatoid arthritis a case report with Classical sonographic features. *Journal of Diagnostic Medical Sonography.* 2015; 31(3):186-189.

Book chapters and other publications

- Lam W, Nag A, Kumar R. Outcomes of Bone Marrow Transplantation. *Contemporary Bone Marrow Transplantation.* 2020; 11-43.

Meeting abstracts

- Nag A, Roychowdhury M, Garg J, Bhava S, Choudhuri S, Nair R, Mallath M, Chandy M. Profile of acute graft-versus-host-disease of the gastrointestinal tract following allogeneic haematopoietic cell transplantation from a tertiary care centre in India. BONE MARROW TRANSPLANTATION. 2019; 54:329-330.
- Radhakrishnan V, Tamboli N, Das S, Garg J, Nag A, Bhava S, Parihar M, Vinarkar S, Mukhopadhyay S, Chakraborty S. Bortezomib-Pomalidomide-Dexamethasone (VPD) As Novel Induction Therapy In Newly-Diagnosed Multiple Myeloma: Early Safety Data from an Ongoing Single Arm Phase-II Investigator-Initiated Clinical Trial (PRIME Study). Blood. 2021; 138:2752.
- Radhakrishnan V, Pattnaik S, Bhadhuri A, Raina V, Mandal P, Bhava S, Garg J, Nag A, Vinarkar S, Parihar M. Induction Mortality In Acute Myeloid Leukemia: A 9 Year Retrospective Study from a Tertiary Care Centre in a Low-Middle Income Country Setting. Blood. 2021; 138:4388.
- Cortes J, Saikia T, Kim D, Alvarado Y, Nicolini F, Rathnam K, Khattri N, Apperley J, Deininger M, de Lavallade H. An Update of Safety and Efficacy Results from Phase 1 Dose-Escalation and Expansion Study of Vobociclib, a Novel Oral BCR-ABL1 Tyrosine Kinase Inhibitor (TKI), in Patients with Chronic Myeloid Leukemia (CML) and Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL) Failing Prior TKI Therapies. Blood. 2021; 138:309
- Iqbal A, Nag A, Bhattacharyya M, Ray S, Choudhuri S. PS1184 ANALYSIS OF BCR-ABL1 TRANSCRIPT LEVELS AT 3 MONTHS IN PREDICTING OVERALL RESPONSE IN PATIENTS OF CHRONIC MYELOID LEUKEMIA-CHRONIC PHASE ON 1ST LINE THERAPY WITH IMATINIB MESYLATE. HemaSphere. 2019; 3(S1):539.
- Iqbal A, Nag A, Bhattacharyya M, Ray S, Choudhuri S. PB1925 COMPARATIVE STUDY OF GLIVEC VERSUS STATE SPONSORED GENERIC IMATINIB MESYLATE AS FIRST LINE THERAPY IN CHRONIC MYELOID LEUKEMIA-CHRONIC PHASE. HemaSphere. 2019; 3(S1):875.
- Javed R, Roychowdhury M, Bhava S, Kumar J, Krishnan S, Nag A, Mishra D, Bhattacharya S, Ks R, Ghara N. HALF-TRUTH: GRAFT CRYOPRESERVATION DOES NOT IMPACT ENGRAFTMENT AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANT (ALLO-HCT)-A SINGLE CENTER EXPERIENCE FROM INDIA. CYTOTHERAPY. 2022; 24(5):S99-S99.
- Tamboli N, Nag A, Radhakrishnan V, Kumar J, Bhava S, Javed R, Bhattacharya S, Goel G, Chatterji S, Mukherjee S. Outcome of sars-cov2 Infection in hematological disorders: A tertiary-care cancer center experience. Indian Journal of Hematology and Blood Transfusion. 2020; :S121-S122.
- Salas M, Atenafu E, Nag A, Bascom O, Wilson L, Lam W, Law A, Pasci I, Al-Shaibani Z, Kim D. Prospective Pilot Study on Frailty and Function Assessment During Clinics in Allogeneic Hematopoietic Cell Transplantation. BONE MARROW TRANSPLANTATION. 2020; 55(SUPPL 1):144-145.

ORCID ID: <https://orcid.org/0000-0002-2120-9570>

NIH Pubmed Link: <https://www.ncbi.nlm.nih.gov/myncbi/arijit.nag.1/bibliography/public/>

Previous participation in clinical trials

Indication of Trial	Clinical Phase of Trial (I-IV)	Role in Trial (e.g. Investigator, Sub-Investigator)	Year in which trial was conducted
CML: A Phase 1 Study to Determine Safety, Tolerability, Pharmacokinetics, and Activity of K0706, a Novel Tyrosine Kinase Inhibitor (TKI) in Subjects with Chronic Myeloid Leukemia (CML)	Phase II	Co- investigator	2020

or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL)			
CMMI A randomized, double-blind, placebo-controlled phase III multi-center study of azacitidine with or without MBG453 for the treatment of patients with intermediate, high or very high risk myelodysplastic syndrome (MDS) as per IPSS-R, or Chronic Myelomonocytic Leukemia-2 (CMMI-2)	Phase III	PI	2021
AML: TATA PRECISION ONCOLOGY PROJECT – ALTITUDE STUDY	Observational / Analytical	CO-I	2020
CLL/ Mantle cell Lymphoma: A prospective, multicenter, open label single arm Phase IV clinical trial to assess safety of Imbruvica (Ibrutinib capsules 140 mg) in Indian patients with chronic lymphocytic leukemia or mantle cell lymphoma who have received at least one prior therapy or chronic lymphocytic leukemia with 17p deletion	Phase IV	PI	2021
CLL/ Mantle cell lymphoma: A prospective, multi-centre, phase IV clinical trial to assess the safety and efficacy of Acalabrutinib capsules in Indian adult patients with chronic lymphocytic leukaemia and relapsed and refractory mantle cell lymphoma	Phase IV	CO-I	2021
A Phase 2a study of HT-6184 in subjects with IPSS-R Very Low, Low or Intermediate Risk Myelodysplastic (MDS) and Symptomatic Anemia.	Phase 2	PI	2024
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Comparing the Efficacy and Safety of Golcadomide Plus R-CHOP Chemotherapy vs Placebo Plus R-CHOP Chemotherapy in Participants with Previously Untreated High-risk Large B-cell Lymphoma (GOISEK-1)	Phase 3	PI	2025
A Randomized, Controlled Phase 3 Study of Pacritinib Versus Physician's Choice in Patients with Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post Essential Thrombocythemia Myelofibrosis with Severe Thrombocytopenia	Phase 3	PI	2024

Platelet Counts & Effect of vpd induction on MRD status in patient of newly diagnosed multiple myeloma (PRIME).	Phase 2	Co-PI	2021-2024
A Phase 1, Open Label, Dose Escalation, Multicenter, First-in-Human (FIH) Study Evaluating the Safety, Pharmacokinetics and Pharmacodynamics of Oral AUR112 in Patients with Relapsed Advanced Lymphoma (ADITI-1).	Phase 1	Co-PI	2025
A Phase 1/2, Open Label, Multicenter Study to Evaluate the Efficacy and Safety of DRL-1801 in Patients with RRMM (SWASTH)	Phase 1/2	Co-PI	2025
A randomized, 2-arm, phase 3 study of elranatamab (pf-06863135) versus lenalidomide in patients with newly diagnosed multiple myeloma after undergoing autologous stem-cell transplantation (MAGNETISM 7).	Phase III	Co-PI	2024
A Phase 1, Open Label, Dose Escalation, Dose Expansion, Multicenter, First in Human (FIH) Study Evaluating the Safety, Pharmacokinetics and Pharmacodynamics of Oral AUR107 in Patients with Relapsed Advanced Malignancies (SHAKTI-1).	Phase 1	Co-PI	2024
A Double-Blind, Randomized clinical study of the efficacy and safety of monotherapy with BCD-264 and Darzalex® in subjects with Relapsed and Refractory Multiple Myeloma (DARVIVA).	Phase 2	Co-PI	2024
An Open Label, Multicenter, Phase IV Study of Teclistamab to Evaluate its Safety in Indian Participants with Relapsed and Refractory Multiple Myeloma who have previously received at least 3 prior lines of therapy including an Immunomodulatory agent, a Proteasome Inhibitor and an Anti-CD38 antibody and have demonstrated disease progression on the last therapy.	Phase IV	Co-PI	2025

Career goals

My Immediate goal is to work towards improving the clinical outcomes in AYA and adults with Acute Lymphoblastic Leukemia using better risk stratification models.

I would also like to work on improving survival outcomes in allogeneic stem cell transplants, especially unrelated donor transplants in Thalassemia and Aplastic anemia, these being some of the major challenges in our healthcare system.

I firmly believe that this can be achieved through collaborative efforts between major tertiary care cancer care / stem cell transplant centers and the national agencies.

Apart from this on a long term perspective, I would like to work towards enriching my skills and spreading the knowledge on the importance of data driven clinical research. More specifically I would like to set up a formal course framework for medical students so that they understand the basics of biostatistics, coding/programming and learn to critically analyze data themselves.

Clinical and research Interests:

- Acute Leukemia (with focus on Acute Lymphoblastic Leukemia)
- Stem cell transplantation (with focus on transplants in Thalassemia and Aplastic Anemia)
- Cancer associated Thrombosis.

Professional interests/hobbies outside Hematology:

- Use of data and statistics in clinical research
- Teaching and mentoring clinical fellows and residents on importance of clinical research and basics of biostatistics.
- Use of R programming in analysis of data.


Courses and certifications:

- o Summer Program in Epidemiology and Biostatistics (SPICE&B) (July 2019); UHN MOT Program.
- o Introduction to Statistics & Data Analysis in Public Health / Logistic Regression in R for Public Health / Survival Analysis in R for Public Health / Linear Regression in R for Public Health by Imperial College London on Coursera: Aug-Dec 2019.
- o Advanced Cardiac Life Support (Heart and Stroke Foundation, Canada): July 2019
- o Basic Cardiac Life Support (Heart and Stroke Foundation, Canada): July 2019
- o Programming for everybody: Getting started with Python: University of Michigan: Feb 2020
- o Quality Clinical Investigator Program: University Health Network, Toronto: Jan 2020

Social bio links:

- LinkedIn Profile: <https://www.linkedin.com/in/arjiti-nag-0135ba8a/>
- Twitter ID: @docarjiti

Dated: May 31, 2025.


Arijit Nag

30-MAR-2026



NIDA Clinical Trials Network

Certificate of Completion

Is hereby granted to

Arijit Nag

to certify your completion of the six-hour required course on:

GOOD CLINICAL PRACTICE

MODULE:

Introduction
Institutional Review Boards
Informed Consent
Confidentiality & Privacy
Participant Safety & Adverse Events
Quality Assurance
The Research Protocol
Documentation & Record-Keeping
Research Misconduct
Roles & Responsibilities
Recruitment & Retention
Investigational New Drugs

STATUS:

N/A
Passed
Passed
Passed
Passed
Passed
Passed
Passed
Passed
Passed
Passed
Passed

Course Completion Date: 24 September 2025

CTN Expiration Date: 24 September 2028

Eve Jelstrom

Eve Jelstrom, Principal Investigator
NDAT CTN Clinical Coordinating Center

Good Clinical Practice, Version 5, effective 03-Mar-2017

This training has been funded in whole or in part with Federal funds from the National Institute on Drug Abuse, National Institutes of Health, Department of Health and Human Services, under Contract No. HHSN27201201000024C.

Arijit Nag
30-MAR-2026



WEST BENGAL MEDICAL COUNCIL

IB 196, Sector-III, Salt Lake
Kolkata - 700 106

Updated Registration Certificate- 2014-2015



Registration No. : 65673
Date of Original Registration : 29-04-2010
Name : NAG
DR. ARIJIT
Father's Name : SRI PRASENJIT NAG
Sex : Male
Address : Permanent : 6/10, SEALS GARDEN LANE,
2ND FLOOR,
PO : COSSIPORE
KOLKATA - 700002
WEST BENGAL INDIA
Present : 6/10, SEALS GARDEN LANE,
2ND FLOOR,
PO : COSSIPORE
KOLKATA - 700002
WEST BENGAL INDIA
Qualification : Basic : M B B S (West Bengal University of Health Sciences), 2010
Additional : M D (Genl. Med.) (West Bengal University of Health Sciences), 2014
• [Regd on 18-06-2014]
D M (Clinical Haematology) (West Bengal University of Health Sciences), 2017
• [Regd on 22-02-2019]

Signature of Applicant Full : *Arijit NAG*
Specimen : *Arijit NAG*

Date : 22-02-2019

Karan Chakrabarti

Registrar, WBMC



An
30-MAR-2026